肾脏疾病中的蛋白质组学与代谢组学:病因、治疗和预防的见解
本综述回顾了蛋白质组学和代谢组学在肾脏疾病研究中的应用,介绍了关键概念、示例和未来方向。蛋白质组和代谢组反映环境暴露和遗传编码的影响,循环水平动态可调,适合治疗靶向。研究设计需根据目标定制,生物标志物发现需调整混杂变量(尤其GFR)并使用严格显著性阈值。质谱和抗体/适配体平台是主要技术,机器学习有助于筛选分子。已有研究在膜性肾病抗原、CKD尿液肽预后、糖尿病肾病炎症蛋白、尿毒症微生物组和AKI生物能量学等方面取得重要成果。
要点
- 蛋白质组和代谢组受环境与遗传共同影响,循环水平动态可调,是潜在治疗靶点。
- 生物标志物发现需调整所有潜在混杂因素(尤其GFR)并采用严格显著性阈值。
- 质谱和抗体/适配体平台是主要技术,机器学习可帮助筛选兴趣分子。
核心结论
- 蛋白质组学和代谢组学已为肾脏疾病病因、治疗和预防提供重要见解,但需更多研究验证和扩展。
研究设计与样本
- 综述性文章,回顾蛋白质组学和代谢组学在肾脏疾病研究中的应用,包括关键概念、示例和未来方向。
主要发现
- 蛋白质组和代谢组反映环境暴露和遗传编码的影响。
- 循环蛋白和代谢物水平动态可调,适合治疗靶向。
- 研究已阐明膜性肾病靶抗原、CKD尿液肽预后特征、糖尿病肾病炎症蛋白介质、微生物组在尿毒症环境中的作用及AKI肾脏生物能量学。
关键数值与推荐
- 生物标志物发现需调整所有潜在混杂变量,尤其GFR,并采用严格显著性阈值。
- 质谱常与前置色谱分离技术联用,是蛋白质组学和代谢组学的主要工具。
- 高通量抗体和适配体平台是分析蛋白质组的强大补充方法。
- 机器学习和通路分析有助于选择最感兴趣的分子并按生物学主题分类。
临床怎么用
- 临床生物标志物发现应调整混杂变量(尤其GFR)并使用严格显著性阈值。
- 机器学习工具和通路分析可用于筛选蛋白质组和代谢组数据中的关键分子。
- 蛋白质组和代谢组发现需在独立队列中验证。
局限性
- 需更多研究在独立队列中重复和扩展发现。
- 需了解特定蛋白和代谢物标志物的纵向轨迹。
- 需在合并数据集中进行跨组学分析,并纳入更多肾脏组织研究。
- 严格显著性阈值可能掩盖生物学信号,且蛋白质组和代谢组高度互相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this review of the application of proteomics and metabolomics to kidney disease research, we review key concepts, highlight illustrative examples, and outline future directions. The proteome and metabolome reflect the influence of environmental exposures in addition to genetic coding. Circulating levels of proteins and metabolites are dynamic and modifiable, and thus amenable to therapeutic targeting. Design and analytic considerations in proteomics and metabolomics studies should be tailored to the investigator's goals. For the identification of clinical biomarkers, adjustment for all potential confounding variables, particularly GFR, and strict significance thresholds are warranted. However, this approach has the potential to obscure biologic signals and can be overly conservative given the high degree of intercorrelation within the proteome and metabolome. Mass spectrometry, often coupled to up-front chromatographic separation techniques, is a major workhorse in both proteomics and metabolomics. High-throughput antibody- and aptamer-based proteomic platforms have emerged as additional, powerful approaches to assay the proteome. As the breadth of coverage for these methodologies continues to expand, machine learning tools and pathway analyses can help select the molecules of greatest interest and categorize them in distinct biologic themes. Studies to date have already made a substantial effect, for example elucidating target antigens in membranous nephropathy, identifying a signature of urinary peptides that adds prognostic information to urinary albumin in CKD, implicating circulating inflammatory proteins as potential mediators of diabetic nephropathy, demonstrating the key role of the microbiome in the uremic milieu, and highlighting kidney bioenergetics as a modifiable factor in AKI. Additional studies are required to replicate and expand on these findings in independent cohorts. Further, more work is needed to understand the longitudinal trajectory of select protein and metabolite markers, perform transomics analyses within merged datasets, and incorporate more kidney tissue-based investigation.
引用
- Dubin RF, Rhee EP. Proteomics and Metabolomics in Kidney Disease, including Insights into Etiology, Treatment, and Prevention. Clin J Am Soc Nephrol. 2019. PMID: 31636087. doi:10.2215/CJN.07420619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。